The MEK and MET Inhibition in Colorectal Cancer (MErCuRIC) study aimed to investigate the MTD, RP2D and safety/tolerability during the dose escalation, and evaluate preliminary anti-tumour activity of combined binimetinib/crizotinib treatment in RASMT CRC patients in the phase Ib study. This evidence concerns the gene MAP2K7 and colorectal cancer.